explore -WSS

explore

author：comprehensive 2025-10-01 17:21:26 - browse：88447

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： What to watch for from Zogenix and Amicus clinical trials

focus

WSS

With FDA staff opposed to Sarepta therapy, top official intervened

What it's like to live with paralysis for one psychologist

Cloning humans is technically possible. It's curious no one has tried

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Dems pitch expanding Medicare power to negotiate drug prices

Roche’s Alnylam deal shows drug firms interested in heart drugs

leisure time

explore

focus

Cancer drug shortages should be causing more outrage

Why we need to separate burnout from moral injury in health care

Medicare details structure of new drug price negotiation program

Colonoscopy at 40? Study finds a possible benefit

Hepatitis C has a cure — but many Americans still lack access to it

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CDC Director Mandy Cohen on transparency, trust, and health

The high cost of giving birth even with insurance

Biden warns of ‘dark winter’ during final presidental debate

knowledge

Will the FTC rein in IQVIA's health data empire?

Rise in cancer among younger people worries and puzzles doctors

CDC concerned about possible undetected monkeypox spread in U.K.

UHS says company favors patients whose insurance pays more

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Biden warns of ‘dark winter’ during final presidental debate

hotspot

focus

focus

entertainment